Polysaccharide pneumococcal vaccination: new evidence

Hall, A. J.
March 2006
Thorax;Mar2006, Vol. 61 Issue 3, p183
Academic Journal
The article looks at the studies of polysaccharide pneumococcal vaccination in elderly or high risk populations. A study which is published in this issue of the journal examines whether the vaccine would prevent community acquired pneumonia in individuals with chronic obstructive airways disease. A concern in all the studies has been the misclassification inherent in using all cause pneumonia as an outcome.


Related Articles

  • Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Alfageme, I.; Vazquez, R.; Reyes, N.; Muñoz, J.; Fernández, A.; Hernandez, M.; Merino, M.; Perez, J.; Lima, J. // Thorax;Mar2006, Vol. 61 Issue 3, p189 

    Background: A study was undertaken to evaluate the clinical efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPY) in immunocompetent patients with chronic obstructive pulmonary disease (COPD). Methods: A randomised controlled trial was carried out in 596 patients with COPD of mean...

  • COMMENTARY: Review: Trials of injectable pneumococcal vaccines do not show effectiveness in chronic obstructive pulmonary disease. McGeer, Allison // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p36 

    The article presents the author's comment on a research study focusing on the role of injectable vaccines in the prevention of pneumococcal infection in patients with chronic obstructive pulmonary disease. The author says that although preventing these infections is clearly desirable, the study...

  • Pneumococcal Polysaccharide Vaccine.  // Annals of Internal Medicine;Feb82, Vol. 96 Issue 2, p203 

    Discusses the recommendations of the Immunization Practices Advisory Committee of the U.S. Centers for Disease Control and Prevention regarding the use of pneumoccocal polysaccharide vaccines against diseases caused by streptoccocus pneumoniae. Information on the vaccines; Effectiveness of the...

  • Children's vaccine licensed for adults.  // Practice Nurse;4/17/2015, Vol. 45 Issue 4, p8 

    The article report on the conjugate pneumococcal vaccine Prevenar from pharmaceutical company Pfizer which has been licensed in Europe for use in adults over the age of 18, and the elderly to help prevent the leading cause of bacterial pneumonia, Streptococcus pneumoniae.

  • Impact of Pneumococcal Vaccination on Pneumonia Rates in Patients with COPD and Asthma. Lee, Todd A.; Weaver, Frances M.; Weiss, Kevin B. // JGIM: Journal of General Internal Medicine;Jan2007, Vol. 22 Issue 1, p62 

    BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are included in several national pneumococcal vaccination recommendations whereas asthma patients are not. The objective of this study was to evaluate pneumonia-related hospitalization risk in patients with COPD or asthma and...

  • Pneumococcal infections and immunization in diabetic patients. Mohan, V.; Unnikrishnan, R.; Thomas, N.; Bhansali, A.; Wangnoo, S. K.; Thomas, K. // Journal of Postgraduate Medicine;Jan-Mar2011, Vol. 57 Issue 1, p78 

    India is today facing a diabetes epidemic and has the maximum number of patients with diabetes in the world. People with diabetes are more prone to develop all types of infections. Pneumococcal infections are a common cause of morbidity and mortality, and people with diabetes are more prone to...

  • Vaccination against pneumococcus in West Africa: perspectives and prospects. Donkor, Eric S.; Dayie, Nicholas T. K. D.; Badoe, Ebenezer V. // International Journal of General Medicine;2013, Vol. 6, p757 

    Background: Pneumococcal vaccination has become obligatory due to the enormous burden of pneumococcal diseases. Quite recently, pneumococcal conjugate vaccines have been developed, and have been shown to be superior to the previous polyvalent polysaccharide vaccine of the organism. Pneumococcal...

  • Pneumococcal Vaccine: The Evidence Mounts. LaForce, Marc // Annals of Internal Medicine;Jan86, Vol. 104 Issue 1, p110 

    Editorial. Explores the efficacy of pneumococcal pneumonia vaccine in the U.S. Results of field trials; Approach in measuring vaccine efficacy; Recommendations on the use of pneumococcal vaccine.

  • Pneumonia Vaccine--Don't Leave Home Without It. Brown, Edwin W. // Medical Update;Mar99, Vol. 22 Issue 9, p4 

    Focuses on pneumonia vaccine in the United States. Types of people eligible for the vaccine; Reasons for people's reluctance to be vaccinated.


Read the Article


Sign out of this library

Other Topics